Aim: To evaluate the cost-effectiveness of stapokibart compared with dupilumab in treating chronic rhinosinusitis with nasal polyps (CRSwNP) from the healthcare system perspective in China. The focus is on assessing the economic viability of biologic treatment... ...

请注册登录后继续浏览